ClinicalTrials.Veeva

Menu
C

Cutting Edge Research Group | Oklahoma City, OK

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lurasidone
Brexpiprazole
Dasotraline
Cariprazine
Ziprasidone
Balovaptan
Divalproex
Lithium
Vilazodone
SPD489

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 59 total trials

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment d...

Active, not recruiting
Attention Deficit Hyperactivity Disorder
Drug: Guanfacine hydrochloride (TAK-503)
Other: Placebo

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

The primary purpose of this trial is to evaluate the safety and tolerability of centanafadine QD XR in pediatric subjects with ADHD.

Active, not recruiting
Attention Deficit/Hyperactivity Disorder
Drug: Centanafadine Hydrochloride

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizop...

Active, not recruiting
Bipolar I Disorder
Schizophrenia
Drug: Cariprazine Flexible Dose

Trial sponsors

Sumitomo Pharma logo
Pfizer logo
Otsuka logo
Forest Laboratories logo
Roche logo
AbbVie logo
Shire logo
Viatris logo
Abbott logo
Purdue Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems